Newsroom

Announcements

  • 24 November 2020

    Jubilant Therapeutics Announces Upcoming Presentation at 2020 ASH Virtual Annual Meeting

    Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases,

    Bedminster, New Jersey, November 24, 2020 – Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that an abstract related to its dual LSD1 and HDAC6 inhibitor, JBI-802, has been accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting taking place Dec. 5-8, 2020

    “We look forward to discussing our novel potent and selective dual inhibitor of LSD1-HDAC6 for the treatment of cancer at the 2020 ASH Virtual Annual Meeting,” said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics. “Our work to progress JBI-802 into the clinic as a potential, differentiated therapeutic for the treatment of select hematological and solid tumors with specific gene signatures is on track and we expect to initiate first-in-human studies in the second half of next year.”

    The abstract, currently available on the ASH conference website, is as follows:

    Title: Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer
    Date: Monday, December 7, 2020
    Session: 802. Chemical Biology and Experimental Therapeutics: Poster III
    Abstract: 3378
    Presenter: Dhanalakshmi Sivanandhan, Ph.D., Associate Vice President & Head of Biology, Jubilant Therapeutics Inc.

    About Jubilant Therapeutics

    Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations. The Company’s entrepreneurial-minded leadership and scientific teams strive for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences Limited’s value chain and shared services. Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.  For more information, please visit www.jubilanttx.com or follow us on Twitter @JubilantTx and LinkedIn.

    Media Contact:
    Kari Watson, +1 781-235-3060
    MacDougall
    kwatson@macbiocom

  • 20 November 2020

    Smt. Smriti Zubin Irani, Hon. Minister of Women & Child Development & Textiles, Government of India, to be the Chief Guest at The Social Entrepreneur of the Year (SEOY) Award - India 2020

    The Schwab Foundation for Social Entrepreneurship, the sister organisation of the World Economic Forum and the Jubilant Bhartia Foundation,

    New Delhi, November 20, 2020: The Schwab Foundation for Social Entrepreneurship, the sister organisation of the World Economic Forum and the Jubilant Bhartia Foundation, a not for profit organisation of Jubilant Bhartia Group are pleased to announce that Smt. Smriti Zubin Irani, Hon. Minister of Women & Child Development & Textiles, Government of India will be the Chief Guest at the 11th Social Entrepreneur of the Year (SEOY) Award - India 2020 on November 26, 2020. The prestigious award will be presented by the Hon. Minister at a virtual award ceremony in presence of esteemed dignitaries and guests from different fields.

    The winner of the SEOY Award – India 2020 will be chosen by a distinguished jury comprising industry stalwarts and eminent personalities from different backgrounds. The winner will join the world’s largest network of social enterprises affiliated with The Schwab Foundation for Social Entrepreneurship.

    The following accomplished social innovators are competing for the coveted SEOY Award - India 2020:

    1. Sujay Santra, iKure, Kolkata – iKure has been working for a decade towards bringing quality, affordable and accessible healthcare at the doorstep of communities in India. It works with the vision of achieving zero mortality due to lack of primary healthcare.

    2. Sandeep Patel, NEPRA, Ahmedabad - With the notion that ‘waste is a commodity’, NEPRA endeavours to solve India’s dry waste management problem through its inclusive, transparent and tech-driven socio-business model.

    3. Ashraf Patel, Pravah & ComMutiny, New Delhi - Pravah has been facilitating the development of a generation of empathetic, sensitive youth change-makers in India through psycho-social interventions, helping them build more inclusive identities and societies bringing about revolutionary changes.

    These social-innovators have been selected from amongst over 100 diverse applications received this year from across 23 cities of India. They have been selected through a rigorous process of evaluation based on various parameters, including background research, personal and on-ground team interactions, impact assessment, expert reviews and reference checks among others. The efforts of these social-innovators are helping bridge the gap between the marginalised and the mainstream in India. For more information on the finalists, read here: https://www.jubilantbhartiafoundation.com/media/press-releases

    Now celebrating its 11th year, the SEOY Awards – India has established itself as one of the most reputed and coveted awards for social entrepreneurs in India. In 2010, the Schwab Foundation for Social Entrepreneurship and Jubilant Bhartia Foundation came together to promote social innovation in India through the Social Entrepreneur of the Year (SEOY) Award - India. The annual award recognises entrepreneurs who implement innovative, sustainable and scalable solutions to solve India’s social problems. These entrepreneurs address pressing issues faced by under-served communities.

    To watch the event live on November 26, 2020 please click on the following links:

    https://www.linkedin.com/company/jubilantbhartiafoundation/
    https://www.youtube.com/channel/UC_bd0RAw2ho_xNh-uXZRLtA
    https://twitter.com/indiaseoy
    https://www.facebook.com/IndiaSEOY
    https://www.jubilantbhartiafoundation.com/social-entrepreneurs-live

    Note to the Editors:

    Schwab Foundation for Social Entrepreneurship was co-founded by Professor Klaus Schwab, Founder and Executive Chairman of the World Economic Forum, and his wife Hilde. For over twenty years, the Schwab Foundation for Social Entrepreneurship has supported the world’s leading social innovators in their efforts to create a more just, equitable, and sustainable world. The Schwab Foundation provides unparalleled platforms at the regional and global level to highlight and advance leading models of sustainable social innovation.
    Learn more at www.schwabfound.org and follow on: Twitter: https://twitter.com/schwabfound

    Jubilant Bhartia Foundation (JBF), established in 2007, is the not-for-profit organisation of the Jubilant Bhartia Group. It focuses on conceptualising and implementing the Corporate Social Responsibility initiatives (CSR) for the Group. The Jubilant Bhartia Foundation’s activities include various community development work, healthcare programs, cultural and sports events, environmental preservation initiative, vocational training, women empowerment, educational activities and promotion of Social Entrepreneurship. www.jubilantbhartiafoundation.com
    Learn more at www.jubilantbhartiafoundation.com and follow on: Twitter: @indiaseoy Facebook: https://www.facebook.com/IndiaSEOY

    For media queries, please contact:
    Vivek Prakash
    Jubilant Bhartia Foundation
    Ph: 9810674758
    E-mail: vivek.prakash@jubl.com

  • 12 November 2020

    Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology

    Biology-driven AI platform uncovers biomarkers used to select optimal targets for new cancer indications Jubilant Therapeutics to advance novel dual LSD1/HDAC6 inhibitor JBI-802 into clinic in 2021

    Biology-driven AI platform uncovers biomarkers used to select optimal targets for new cancer indications Jubilant Therapeutics to advance novel dual LSD1/HDAC6 inhibitor JBI-802 into clinic in 2021.

    Bedminster, NJ and New York, NY— November 12, 2020 — Jubilant Therapeutics Inc. (‘Jubilant’), a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, and OneThree Biotech, a company redesigning drug discovery with biology-driven artificial intelligence, today announced their collaboration and the successful completion of a study focused on the identification of specific biomarkers for new indications in targeted oncology patient populations.

    As part of the collaboration, Jubilant Therapeutics sought to determine the mechanism for its potentially first-in-class dual epigenetic inhibitor targeting melanoma, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) and select solid tumor subsets. Utilizing the OneThree Biotech platform, they were able to:

    • Generate new data to support the dual inhibition (LSD1 and HDAC6) to drive inhibition
    • Pinpoint molecular markers that could be used to identify patients who might benefit from the dual inhibition
    • Determine additional target indications for future trials

    “The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection,” said Syed Kazmi, President and CEO of Jubilant Therapeutics. “Jubilant Therapeutics has a strong biomarker-driven innovation platform and we are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach to streamline the delivery of right medicines to right patients who may not be currently benefiting from available cancer therapies.”

    “We’ve been incredibly impressed with Jubilant Therapeutics’ approach of combining focused experimentation with mechanistic biology and how they have re-thought the drug development process through the inclusion of new technology like AI. We’ve seen how results from this partnership can shape downstream clinical development and are excited to see it continue to evolve.” said Neel S. Madhukar, PhD, co-founder and CEO of OneThree Biotech.

    A challenge in traditional drug development is generating an understanding of the biological mechanisms that drive the efficacy of a small molecule compound. OneThree Biotech has built an AI-powered platform that integrates over 40 data types to understand these underlying mechanisms and how they link drugs, targets and patients. This comprehensive approach enables delivery of informed insights to biopharma partners at critical stages of the development process.

    JBI-802 is currently being evaluated in IND-enabling studies for the treatment of hematological and select solid tumors with specific gene signatures and first-in-human clinical studies are expected in 2021. Jubilant Therapeutics Inc. is developing a pipeline of novel, differentiated therapeutic assets; for partnership opportunity inquiries please contact bd@jubilanttx.com.

    About Jubilant Therapeutics Inc.

    Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations. The Company’s entrepreneurial minded leadership and scientific teams strive for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences Limited’s value chain and shared services. Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members. For more information, please visit www.jubilanttx.com or follow on Twitter @JubilantTx and LinkedIn.

    About OneThree Biotech
    OneThree Biotech has built a biology-driven artificial intelligence (AI) platform that optimizes preclinical drug discovery and development by quickly and accurately generating new testable insights and hypotheses. With over 20 peer review journals, multiple case studies, and success advancing lead candidates through clinical trials, our proven technology platform integrates more than 40 types of chemical, biological, and clinical data with the best computational tools to answer complex questions surrounding disease biology and drug discovery. OneThree Biotech is based in New York City and can be found online at www.onethree.bio and on Twitter at @OneThreeBiotech.

    Media Contacts
    MacDougall for Jubilant Therapeutics Inc.
    Holly Hancock or Susan Sharpe
    hhancock@macbiocom.com or ssharpe@macbiocom.com
    (781) 235-3060

    Bioscribe for OneThree Biotech
    Colin Sanford
    colin@bioscribe.com
    (203) 918-4347

    SOURCES: Jubilant Therapeutics Inc. and OneThree Biotech

  • 06 November 2020

    Jubilant Pharma Ltd. and Aavis Pharmaceuticals launch Hydroxychloroquine Sulfate tablets in the U.S. market

    Yardley, PA and Hoschton, GA – November 6, 2020 (PRNewswire) - Jubilant Pharma Ltd. and Aavis Pharmaceuticals Inc.

    Yardley, PA and Hoschton, GA – November 6, 2020 (PRNewswire) - Jubilant Pharma Ltd. and Aavis Pharmaceuticals Inc. announce the launch of Hydroxychloroquine Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil (hydroxychloroquine sulfate) 200 mg in the U.S. market. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd.

    Hydroxychloroquine Sulfate Tablets are indicated for the treatment of Malaria, Lupus Erythematosus and Rheumatoid Arthritis. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S. through our marketing partner.” stated Ashok Barot, Chairman, Aavis Pharmaceuticals. “Our team is doing their best to fulfil the current surge in demand. We’ll continue our efforts to be a significant and reliable supplier of this product.” stated Swapnil Shah, Managing Director, Senores Pharmaceuticals, R&D partner and an affiliate of Aavis Pharmaceuticals.

    “We are excited about this launch” stated Pramod Yadav, CEO, Jubilant Pharma Limited. “We are pleased to partner with Aavis to create access for the growing demand for this product and expand our basket of offerings in the US market.”

    U.S. annual market size for Hydroxychloroquine Sulfate Tablets, 200 mg was approximately US$237 million (IQVIA MAT June 2020).

    About Havix Group Inc. D/B/A Aavis Pharmaceuticals

    Aavis Pharmaceuticals, based in Atlanta, Georgia is one of the fastest growing pharmaceutical companies in the U.S. market. Currently, the company has more than 12 products commercially launched or filed with the USFDA.

    For more information about Aavis Pharmaceuticals, please visit  www.aavispharma.com

    About Senores Pharmaceuticals Pvt. Ltd.

    Senores Pharmaceuticals is an Ahmedabad, India based R&D partner and an affiliate of Aavis Pharmaceuticals. It is involved in product development and marketing in the USA and ROW markets.

    About Jubilant Pharma Limited

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non Sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of 49 radiopharmacies in the US. The Company has a team of around 5,200 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

    For more information about Jubilant Pharma, please visit www.jubilantpharma.com

    About Jubilant Cadista Pharmaceuticals Inc.

    Jubilant Cadista Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company in the United States devoted to discovery, manufacture, sale, and distribution of prescription generic pharmaceutical products.

    To learn more about Jubilant Cadista, please visit our website: www.cadista.com.

    Jubilant Pharma Ltd.
    6 Temasek Boulevard, #20-06
    Suntec City Tower Four, Singapore 038986
    Tel.: +65 6235 4129
    www.jubilantpharma.com

    Jubilant Pharma Holdings Inc.
    790 Township Line Road, Suite 175
    Yardley, PA 19067, USA
    Tel.: +1 215 550 2810

    Aavis Pharmaceuticals
    9488 Jackson Trail Road,
    Hoschton, GA, 30548
    Tel.: +1 706 684 0388
    www.aavispharma.com

    Senores Pharmaceuticals Pvt. Ltd.
    11th Floor, South tower,
    ONE42, Ambli - Bopal Rd,
    Ahmedabad, Gujarat 380058
    Tel.: +91 027 17402533

  • 04 November 2020

    JUBILANT LIFE SCIENCES – Q2 & H1’FY21 RESULTS

    The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, met today to approve financial results for the quarter ended September 30, 2020.

    • Q2’FY21 Revenue at Rs 2,375, Crore vs. Rs 2,266 Crore in Q2’FY20
    • Q2’FY21 EBITDA at Rs 493 Crore vs. Rs 481 Crore in Q2’FY20
    • H1’FY21 Revenue at Rs 4,268 Crore vs. Rs 4,448 Crore in H1’FY20
    • H1’FY21 EBITDA at Rs 804 Crore vs. Rs 925 Crore in H1’FY20

    The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, met today to approve financial results for the quarter ended September 30, 2020.

    Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:

    “Q2’FY21 has witnessed a substantial improvement over the previous quarter despite continued adverse impact of the COVID-19 pandemic in at least the first half of Q2.

    The company’s performance in the LSI business has been better in EBITDA as well as in margins both year-on-year as well as quarter-on-quarter due to good demand and improved pricing of select products. We maintained business continuity in all the manufacturing sites. DDDS segment witnessed strong year-on-year growth in revenues led by healthy demand from customers.

    Pharma business performance improved substantially QoQ led by growth in CMO and Generics. Radiopharma continued to have a temporary negative impact due to COVID-19 related restrictions on hospital visitations. With the gradual opening of the US healthcare markets, demand conditions have started improving and Allergy business is already at Pre-COVID level during Q2’FY21. We continue to see new business opportunities in CDMO, Generics and Specialty Pharma segments.

    With the strong demand recovery and new business sign-ups, we expect strong performance in our Pharma, LSI and DDDS businesses in the H2’FY21.

    During H1’FY21, the Company reduced net debt on a constant currency basis by Rs 193 Crore.”

    Q2’FY21 Highlights

    A. Consolidated

    • Revenue at Rs 2,375 Crore, as compared with Rs 2,266 Crore in Q2’FY20
    • Reported EBITDA at Rs 493 Crore as compared with Rs 481 Crore in Q2’FY20. EBITDA margin at 20.8% vs. 21.2% in Q2’FY20
    • Finance costs at Rs 64 Crore vs. Rs 72 Crore in Q2’FY20
    • Net Profit at Rs 224 Crore versus Rs 249 Crore in Q2’FY20. EPS of Rs 14.1 vs. Rs 15.7 in Q2’FY20. Q2’FY20 had lower tax incidence due to deferred tax liability reversal of Rs 50 Crore. Adjusting for the tax reversal, PAT is up 12% YoY.
    • Capital expenditure for the quarter was Rs 110 Crore

    Jubilant Life Sciences Ltd.
    1A, Sector 16A, Noida – 201301, India
    Tel.: +91 120 4361000
    www.jubl.com

    Segment Wise Analysis

    B. Pharmaceuticals Segment

    • Pharmaceuticals revenue was at Rs 1,516 Crore vs. Rs 1,452 Crore in Q2’FY20
    • Pharmaceuticals EBITDA recorded at Rs 343 Crore as compared with Rs 386 Crore in Q2’FY20 with a margin of 22.6% as compared to 26.6% in Q2’FY20
    • R&D spent during the quarter of Rs 51 Crore – 3.3% to segment sales. R&D debited to P&L is Rs 40 Crore – 2.6% to segment sales
    • The Company launched its remdesivir product under the brand name ‘JUBI-R’ in India and other markets in the first week of August 2020. Further to this, the Company has launched its remdesivir product in multiple countries and filed dossiers in several others
    • Strategic partnership with SOFIE Biosciences, an innovation leader in molecular theranostics. Jubilant, with 25% equity holding, will be the largest shareholder of SOFIE. SOFIE’s business lines are highly synergistic to Jubilant Radiopharma

    C. Life Science Ingredients Segment

    • LSI revenue was at Rs 784 Crore against Rs 753 Crore in Q2’FY20
    • Strong growth in revenue is driven by improved pricing in Nutritional products & Specialty Intermediates segments and higher demand in Life Sciences Chemical
    • EBITDA at Rs 139 Crore increased by 52% YoY with margin of 17.7% as compared to 12.1% in Q2’FY20
    • Strong improvement in profitability is driven by improvement in prices of Nutritional Products and Specialty Intermediates

    D. Drug Discovery & Development Solutions Segment

    • Revenue at Rs 75 Crore increased by 23% YoY led by growth in Drug Discovery Services business
    • Reported EBITDA at Rs 21 Crore vs. Rs 19 Crore in Q2’FY20 with a margin of 27.4% vs. 30.5% in Q2’FY20
    • In July 2020, the company announced completion of the merger of Jubilant Chemsys Limited with Jubilant Biosys Limited. The combined entity will operate as Jubilant Biosys Limited. The merger will simplify operations and provide customers with a single brand access for a wide range of discovery, IND and PR&D and GMP development services

    H1’FY21 Highlights

    E. Consolidated

    • Consolidated Revenue at Rs 4,268 Crore vs. Rs 4,448 Crore in H1’FY20
    • EBITDA at Rs 804 Crore vs. Rs 925 Crore in H1’FY21. EBITDA margin at 18.8% vs. 20.8% in H1’FY20
    • Finance costs at Rs 140 Crore down 3% YoY
    • Net Profit at Rs 312 Crore vs. Rs 434 Crore in H1’FY20. EPS of Rs 19.6 vs. Rs 27.3 in H1’FY20
    • Capex in H1’FY21 of Rs 199 Crore
    • Net debt is down by Rs 193 Crore during H1’FY21

    Segment Wise Analysis

    F. Pharmaceuticals Segment

    • Pharmaceuticals revenue at Rs 2,612 Crore vs. Rs 2,781 Crore in H1’FY21
    • EBITDA at Rs 521 Crore vs. Rs 716 Crore in H1’FY20. Margin of 20.0% as compared to 25.7% in H1’FY20
    • R&D spent during H1 at Rs 107 Crore – 4.1% to segment sales. R&D debited to P&L is Rs 83 Crore – 3.2% to segment sales

    G. Life Science Ingredients Segment

    • LSI revenue at Rs 1,520 Crore vs Rs 1,559 Crore in H1’FY21
    • EBITDA at Rs 263 Crore up 23% YoY with margin of 17.3% as compared to 13.7% in H1’FY20

    H. Drug Discovery & Development Solutions Segment

    • Revenues at Rs 132 Crore up 21% YoY
    • EBITDA was at Rs 38 Crore up from Rs 30 Crore in H1’FY20

    I. Business Outlook

    • We continue to see improvement in demand in most of our business segments be it Specialty Pharma, CMO, API or Specialty Intermediates
    • Given the strong demand recovery and new business sign-ups, we believe COVID-19 is not likely to have a material impact on our overall performance during FY21, provided the pandemic situation does not materially deteriorate going forward
    • Overall, we expect strong performance in our Pharma, LSI and DDDS business in the second half of FY21
    • For Pharmaceutical business, we expect Q3 and Q4 performance to further improve over Q2
    • For LSI business, we expect to achieve close to double digit growth in revenues and significant growth in EBIDTA with higher margins and a very healthy cash generation in FY21
  • 04 November 2020

    Jubilant Therapeutics to Participate in Upcoming Investor Conferences

    Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases,

    Bedminster, New Jersey – November 04, 2020 – Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that Company management will participate in three upcoming investor conferences.

    - The Credit Suisse 29th Annual Healthcare Conference taking place November 9-12. Jubilant Therapeutics will present virtually on Wednesday, November 11 at 8:00 a.m. Eastern Time (ET). Click Here to register and attend.

    - The LSX Investival Showcase taking place November 11-16. Jubilant Therapeutics will share a company presentation virtually during this event that would be available on the event portal. Click Here to register and attend.

    - The Jefferies 2020 Virtual London Healthcare Conference taking place November 17-19. Jubilant Therapeutics will virtually attend this conference and will be available for meetings. Click Here to register and attend.

    About Jubilant Therapeutics Inc.

    Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations. The Company’s entrepreneurial minded leadership and scientific teams strive for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences Limited’s value chain and shared services. Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members. For more information, please visit www.jubilanttx.com or follow us on Twitter @JubilantTx and LinkedIn.

    Media Contacts
    MacDougall for Jubilant Therapeutics Inc.
    Holly Hancock or Susan Sharpe
    hhancock@macbiocom.com or ssharpe@macbiocom.com
    (781) 657-9097

  • 04 November 2020

    Jubilant Radiopharma and SOFIE Biosciences Ink Strategic Partnership Deal to Further Advance the Field of Molecular Imaging & Therapeutics

    Yardley, PA and Dulles, VA – November 4, 2020. SOFIE Biosciences, Inc. (“SOFIE”), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization,

    Yardley, PA and Dulles, VA – November 4, 2020. SOFIE Biosciences, Inc. (“SOFIE”), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited announced that both the organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, via one of its wholly owned subsidiaries, with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to continue to grow production capacity, advance its theranostic pipeline, and support novel PET diagnostic manufacturing and distribution within the U.S.

    “SOFIE is a beacon of innovation, and with Jubilant’s deep experience, uncompromised quality and customer-centric operations, we will bring game-changing theranostic solutions to nuclear medicine” stated Sergio Calvo, President of Jubilant’s Radiopharmaceuticals Division.

    “With this new relationship, SOFIE achieves another milestone in our innovation strategy” Philipp Czernin, SOFIE’s Chief Revenue Officer, remarked. “By engaging a well-established industry partner such as Jubilant Radiopharma, SOFIE will leverage the combined market presence and astute organizational structure to deliver breakthrough compounds to the nuclear medicine community. With respective distribution capabilities and the highly complementary product portfolio of SPECT and PET radiopharmaceuticals, both companies are well poised to create a single-vendor opportunity in select geographies.”

    As part of the agreement, Jubilant Radiopharma will invest US$25m into SOFIE Biosciences. This funding will help accelerate the readiness timelines for SOFIE’s state-of-the-art Theranostics Center of Excellence Manufacturing Facility in Totowa, New Jersey, as well as advance the development of their Fibroblast Activation Protein Inhibitor (FAPI) program. Patrick Phelps, SOFIE’s President and Chief Executive Officer stated “Under this strategic partnership, SOFIE is excited to meet the growing need to manufacture highly specialized radiopharmaceuticals, as well as become the first theranostic production center for FAPI in the US. FAPI has received worldwide acclaim for its value as a key next-generation theranostic agent with the ability to greatly enhance the detection and treatment of a wide variety of oncology diseases, and we believe with Jubilant Radiopharma’s investment and support, we can accelerate the development and commercialization of this exciting family of compounds.”

    “This agreement is yet another demonstration of Jubilant Radiopharma’s long term commitment to the global Nuclear Medicine community. Our teams are dedicated to bringing to market the next generation of breakthrough products and industry leading services to healthcare providers across the globe as part of our mission of Improving Lives Through Nuclear Medicine,” stated Pramod Yadav, CEO Jubilant Pharma Limited.

    About SOFIE Biosciences, Inc

    SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine.

    For further information about About SOFIE Biosciences, Inc
    E-mail: info@sofie.com
    Visit our website @ https://sofie.com

    About Jubilant Pharma Limited

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Life Sciences Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non Sterile products through six US FDA approved manufacturing facilities in the US, Canada and India and a network of 49 radiopharmacies in the US. The Company has a team of around 5,200 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

    About Jubilant Radiopharma

    Jubilant Radiopharma, Radiopharmaceutical Division of Jubilant Pharma Ltd., is an industry-leading radiopharmaceutical business focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of “Improving Lives Through Nuclear Medicine” on a global scale. The company is the market leader in North America for I-131 products (diagnosis and treatment of thyroid disorder and cancer), MAA (lung perfusion imaging), DTPA (renal, brain imaging) and MDP (bone imaging), and also markets other products such as Sestamibi (myocardial perfusion imaging), Gluceptate (brain and renal imaging), and Rubidium-82 Generator (PET Cardiology).

    For further information about Jubilant Radiopharma
    E-mail: robert.sgroi@jubl.com (Robert Sgroi, Director of Marketing)
    Visit our website @ www.jubilantradiopharma.com

    For further information about Jubilant Pharma Limited
    E-mail: hemant.bakhru@jubl.com (Hemant Bakhru, Head - Investor Relations)
    Visit our website @ www.jubilantpharma.com

  • 02 November 2020

    Three outstanding social innovators contest for ‘Social Entrepreneur of the Year’ Award - India 2020

    The Schwab Foundation for Social Entrepreneurship, the sister organisation of the World Economic Forum and the Jubilant Bhartia Foundation,

    New Delhi, November 2, 2020: The Schwab Foundation for Social Entrepreneurship, the sister organisation of the World Economic Forum and the Jubilant Bhartia Foundation, a not for profit organisation of Jubilant Bhartia Group today announced the finalists of the 11th Social Entrepreneur of the Year (SEOY) Award - India 2020.

    The winner will be chosen by a distinguished jury comprising industry stalwarts and eminent personalities from different backgrounds. The winner of SEOY Award India will join the Schwab Foundation for Social Entrepreneurship community, a prestigious network of social innovators from around the world.

    The following accomplished social innovators have been selected as finalists for the SEOY Award - India 2020:

    1. Sujay Santra, iKure, Kolkata

    2. Sandeep Patel, NEPRA, Ahmedabad

    3. Ashraf Patel, Pravah & ComMutiny, New Delhi

    These social innovators have been selected through a rigorous process of evaluation based on various parameters, including background research, personal and on-ground team interactions, impact assessment, expert reviews and reference checks among others. The chosen finalists are tech-enabled, accomplished social entrepreneurs working in the fields of waste management, rural health and youth leadership. Their efforts are helping to bridge the gap between the marginalised and the mainstream in India. Using disruptive innovation in their respective initiatives, these innovators are bringing change through livelihood generation for rural women, improving primary health facilities, organising BoP communities of rag pickers and shaping vulnerable groups of adolescents and youth.

    The SEOY Award - India 2020 opened in March this year and received over 100 diverse applications from 23 cities including 20 applications from women social entrepreneurs. The categories of the intervention included clean technology, media communication, disability, energy, enterprise development, labour conditions, microfinance, sustainable farming and water & sanitation.

    Out of the total number of applications, health sector leads the nomination tally with (47%) applications followed by the environment (37%) education and livelihood (35%) and rural development (23%).

    Now celebrating its 11th year, the SEOY Awards India has established itself as one of the most reputed and coveted awards for social entrepreneurs in India. In 2010, the Schwab Foundation for Social Entrepreneurship and Jubilant Bhartia Foundation came together to promote social innovation in India through the Social Entrepreneur of the Year (SEOY) Award - India. The annual award recognises entrepreneurs who implement innovative, sustainable and scalable solutions to solve India’s social problems. These entrepreneurs address pressing issues faced by under-served communities.

    Brief Descriptions of the Finalists

    Sujay Santra
    iKure, Kolkata
    www.ikuretechsoft.com

    With the inspirational dream of achieving zero mortality due to lack of primary healthcare in India, iKure has been working towards bringing quality, affordable, and accessible healthcare to the doorstep of communities for over a decade. iKure delivers primary healthcare, wellness & prevention services through innovative technology, trained frontline community health workers, a network of Hub & Spoke clinics with a focus on the continuum of care across rural, semi-urban as well urban settings.

    Its doorstep community health workers are equipped with point-of-care (POC) devices, which enables them to provide monitoring and diagnostic support. In the geographical areas where it operates iKure offers wide-ranging health services packages, door-to-door consultation assisted telemedicine with appropriate referral and escalation, drugs and medical supplies, pathological tests, eye & dental tests, and spreads awareness among others. Through its proprietary software, Wireless Health Incident Monitoring System (WHIMS) iKure analyses patient information for health screening, early detection, and monitoring of diseases. It brings in data science and research capabilities to analyze collected data and find the root causes of ailments and addresses them holistically through a combination of health & hygiene, water & sanitation, nutrition, etc.

    With its unique combination of technology intervention, skill development, and outreach initiatives iKure has served a population of over 10.2 million people in 5,200 villages across 7 states of India. With the belief in co-creation, it has created a unique ecosystem by partnering with local NGOs for on-ground mobilization, device partners for the latest technology, supply chain partners for consumables, hospitals for secondary & tertiary care and research organisations for clinical & technical knowhow of various ailments.

    Sandeep Patel
    NEPRA, Ahmedabad
    www.letsrecycle.in

    NEPRA endeavours to solve India’s dry waste management problem through its inclusive, transparent and tech-driven socio-business model. NEPRA’s waste management services spread pan-India include Environmental compliance Advisory, collection, waste processing & recycling by creating state of the art Material Recovery Facilities. NEPRA has been demolishing the challenges faced by the Indian waste management sector one by one through its simple strategy of ‘Innovate and Improvise’, NEPRA works with the motto of ‘Zero waste to landfill’.

    NEPRA engages in city-level waste management services, ranging from awareness and collection of dry waste from several big & small waste generators to sorting (according to the type of waste), processing it at its mechanized Material Recovery Facilities (MRF) and finally recycling it. The waste processed into recyclable form is traded to recyclers to churn new products and non-recyclables are channelled for energy recovery. NEPRA’s model makes the informal sector workers (waste-pickers, sweepers, and other Bottom of the Economic Pyramid members) as one of its main stakeholders. It helps in organising the unorganised waste management sector and changes the way waste is collected and dumped through the use of technology like GPS, Facial Recognition making it more efficient and transparent. Through Facial recognition, NEPRA has helped create first of its kind database of the waste pickers in the cities where it operates. It has helped curb exploitation by ensuring fair and equal payment to waste pickers, who in turn are also trained and employed at NEPRA’s MRF facilities giving them economic security.

    NEPRA has so far engaged with over 2000+ waste pickers. For multi-layered packaging, NERPA has it’s tie-ups with urban local bodies and upliftment of small waste management NGOs or start-ups in 18 states in India. In last one year, NEPRA has worked with 40 local Government authorities. In the last two years, NEPRA has successfully recycled 67108.93MT of dry waste.

    Ashraf Patel
    Pravah & ComMutiny- The Youth Collective, New Delhi
    www.pravahindia.org; www.commutiny.in

    Pravah has been facilitating the development of a generation of empathetic, sensitive youth change-makers in India through psycho-social interventions, helping them build more inclusive identities and societies bringing about revolutionary changes. With a belief that leaders are created in spaces which are safe, empowering, and inclusive, a unique approach to youth development in the form of the ‘5th Space’ has been developed. The 5th Space focuses on transforming young people by engaging them in deep self-exploration and supporting their social action experiments to become change-makers and awakened active citizens. It nurtures social inclusion, holistic development and fosters social hope by promoting feelings of freedom, ownership, love and learning and growth. With credence in its strategy and approach of creating ‘Abilities beyond skill’ Pravah has produced over 50 different designs of self to society journeys for different youth audiences ranging from urban middle-class young people to youth from rural and tribal backgrounds.

    ComMutiny - The Youth Collective, was incubated by Pravah in collaboration with some of the best youth engaging organisations in the country and is a sustainable and vibrant national community of practice that nurtures 5th Spaces with and for young people, through joint programming, partnerships, capacity building and public engagement on contemporary issues focusing on youth-centric development and constitution values. A multi-sectoral formulation, called the vartaLeap coalition is also emerging from this eco-system to realise the mission of 'Every Youth a Jagrik and Every Space Nurturing Jagriks', that places youth duties and rights at the centre of all programming and policies in relation to youth and spaces that engage and influence young people in the country.

    Together Pravah and ComMutiny- The Youth Collective (CYC) have nurtured 6,80,000 young leaders, worked with over 1200 youth-centric organisations and 100 civil society groups across 17 states in the country. The organisations have nurtured and empowered spaces with and for young people, through joint collaborative programming and partnerships; capacity building of people and organisations and engaging with multiple stakeholders in the adolescent and youth space.

    Note to the Editors:

    Schwab Foundation for Social Entrepreneurship was co-founded by Professor Klaus Schwab, Founder and Executive Chairman of the World Economic Forum, and his wife Hilde. For over twenty years, the Schwab Foundation for Social Entrepreneurship has supported the world’s leading social innovators in their efforts to create a more just, equitable, and sustainable world. The Schwab Foundation provides unparalleled platforms at the regional and global level to highlight and advance leading models of sustainable social innovation.

    Learn more at www.schwabfound.org and follow on: Twitter: https://twitter.com/schwabfound

    Jubilant Bhartia Foundation (JBF), established in 2007, is the not-for-profit organisation of the Jubilant Bhartia Group. It focuses on conceptualising and implementing the Corporate Social Responsibility initiatives (CSR) for the Group. The Jubilant Bhartia Foundation’s activities include various community development work, healthcare programs, cultural and sports events, environmental preservation initiative, vocational training, women empowerment, educational activities and promotion of Social Entrepreneurship. www.jubilantbhartiafoundation.com

    Learn more at www.jubilantbhartiafoundation.com and follow on: Twitter: @indiaseoy
    Facebook: https://www.facebook.com/IndiaSEOY

    For media queries: Vivek Prakash
    Jubilant Bhartia Foundation
    Ph: +91 120 436 1805/ 1811
    E-mail: vivek.prakash@jubl.com

  • 20 October 2020

    Jubilant Therapeutics Strengthens Scientific Advisory Board

    BEDMINSTER, NJ, USA – October 20, 2020 – Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases,

    BEDMINSTER, NJ, USA – October 20, 2020 – Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that three new thought leaders in the field of cancer genetics will join the Company’s Scientific Advisory Board. These thought leaders will provide external scientific review and advice to the Jubilant leadership team on research and development activities.

    “We are pleased to welcome these distinguished experts to our Scientific Advisory Board,” said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics Inc. “The depth of their collective expertise and experience will be extremely valuable as we work to progress our programs towards the clinic. We look forward to collaborating with these highly skilled and imaginative scientists” he further added.

    The Scientific Advisory Board will help support the advancement of Company’s differentiated portfolio, including a unique LSD1/HDAC6 dual inhibitor positioned to address hematological cancers and solid tumors, a next-generation, potential first-in-class PAD4 inhibitor targeting inflammation-driven diseases and autoimmune disorders, as well as novel small molecule PRMT5 and PD-L1 inhibitors for oncology.

    About the New Members

    Julian Downward, PhD, Associate Research Director, Division of Molecular Pathology at the Institute of Cancer Research at the Francis Crick Institute. Dr. Downward’s work focuses on the role played by major oncogenes such as RAS and EGFR in human cancer.

    William C. Hahn, MD, PhD, Chief Scientific Officer, William Rosenberg Professor of Medicine at the Dana-Farber Cancer Institute. Dr. Hahn’s discoveries have informed our current molecular understanding of cancer and formed the foundation of new translational studies. His laboratory pioneered the use of integrated functional genomic approaches to identify and validate cancer targets.

    Ross Levine, MD, Chief, Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. As a physician-scientist, Dr. Levine’s laboratory focuses on elucidating the genetic basis of myeloid malignancies.

    About Jubilant Therapeutics Inc.

    Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations. The Company’s entrepreneurial-minded leadership and scientific teams strive for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences Limited’s value chain and shared services. Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.  For more info please visit: www.jubilanttx.com

  • 04 September 2020

    JUBILANT LIFE SCIENCES – Q1’FY21 RESULTS

    The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, met today to approve financial results for the quarter ended June 30, 2020.

    • Q1’FY21 Revenue at Rs 1,893 Crore vs. Rs 2,182 Crore in Q1’FY20;
    • Q1’FY21 EBITDA at Rs 310 Crore vs. Rs 444 Crore in Q1’FY20

    The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, met today to approve financial results for the quarter ended June 30, 2020.

    Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:
    “During the quarter, we worked diligently towards employees’ safety while continuing to serve our global customers by maintaining our operations.
    The company’s performance in the LSI business has been better in EBITDA as well as in margins on both year-on-year as well as quarter-on-quarter due to good demand and improved pricing of select products. We maintained business continuity in all the manufacturing sites. DDDS segment witnessed year-on-year growth in revenues as well as EBITDA led by healthy demand from customers.
    The Company’s performance in the Pharma business had a temporary negative impact due to production suspension at our API plant. This facility has resumed operations from the month of June 2020 and since then it has been operating at a normal capacity. We are witnessing strong demand conditions and improved pricing environment. Our Radiopharma and Allergy business saw an interim decline in revenues due to postponement of elective procedures led by COVID-19 related restrictions on hospital visitations. Adverse impact in these businesses was mitigated by growth in CMO and Dosage businesses.
    With the gradual opening of the US healthcare markets, demand conditions in our Radiopharma and Allergy business have started improving from second half of Q1’FY21 with substantial normalisation achieved June 2020 onwards. In our CMO business, we have entered into four separate clinical and commercial supply agreements for the GMP manufacture of novel COVID-19 treatment and vaccine candidates. Strong demand conditions in this business, along with our business development initiatives, promise upside to performance in the near term.
    Overall, barring unforeseen circumstances, we expect strong performance in our Pharma, LSI and DDDS business in the remaining three quarters of FY21. During Q1’FY21, the Company reduced net debt on a constant currency basis by Rs 343 Crore.
    In the first week of August 2020, the Company launched its remdesivir product in the India and other countries under the brand name ‘JUBI-R’.
    The Company has taken several measures to tide over the COVID-19 induced challenges. We are confident of delivering sustained growth in the medium term on back of our leadership position in various businesses and growth strategies.

    Q1’FY21 Highlights

    Consolidated

    • Revenue at Rs 1,893 Crore, as compared with Rs 2,182 Crore in Q1’FY20
    • Reported EBITDA at Rs 310 Crore as compared with Rs 444 Crore in Q1’FY20. EBITDA margin at 16.4% vs. 20.4% in Q1’FY20
    • Adjusted EBITDA after one-off expenses at Rs 318 Crore as compared with Rs 478 Crore in Q1’FY20. Adjusted EBITDA margin for the quarter was 16.8% vs. 21.9% in Q1’FY20
    • Finance costs at Rs 76 Crore vs. Rs 73 Crore in Q1’FY20
    • Net Profit at Rs 88 Crore versus Rs 185 Crore in Q1’FY20. EPS of Rs 5.53 vs. Rs 11.61 in Q1’FY20
    • Capital expenditure for the quarter was Rs 71 Crore
    • Net debt on a constant currency basis reduced by Rs 343 Crore during Q1’FY21

    Pharmaceuticals Segment

    A. Pharmaceuticals Segment

    • Pharmaceuticals revenue was at Rs 1,096 Crore vs. Rs 1,328 Crore in Q1’FY20
    • Pharmaceuticals EBITDA at Rs 179 Crore as compared with Rs 330 Crore in Q1’FY20 with a margin of 16.3% as compared to 24.8% in Q1’FY20
    • Pharmaceuticals adjusted EBITDA at Rs 184 Crore vs. Rs 355 Crore in Q1’FY20 with a margin of 16.8% as compared to 26.8% in Q1’FY20
    • R&D spent during the quarter of Rs 57 Crore – 5.2% to segment sales. R&D debited to P&L is Rs 43 Crore – 3.9% to segment sales
    • The Company launched its remdesivir product under the brand name ‘JUBI-R’ in India and other markets in the first week of August 2020

    B. Life Science Ingredients Segment

    • LSI revenue was at Rs 737 Crore against Rs 805 Crore in Q1’FY20
    • Strong growth witnessed in Nutritional Products business though Specialty Intermediates and Life Science Chemicals businesses faced headwinds due to temporary impact on demand during beginning of quarter due to COVID-19
    • EBITDA at Rs 124 Crore increased by 2% YoY with margin of 16.8% as compared to 15.1% in Q1’FY20
    • Strong improvement in profitability of Nutritional Products and Specialty Intermediates businesses, driven by better product prices including that of Vitamin B3

    C. Drug Discovery & Development Solutions1 Segment

    • DDDS revenue at Rs 60 Crore increased by 26% YoY led by growth in Drug Discovery Services business
    • EBITDA at Rs 15.7 Crore vs. Rs 8.5 Crore in Q1’FY20 with a margin of 26.0% vs. 17.7% in Q1 last year
    • In July 2020, the company announced completion of the merger of Jubilant Chemsys Limited with Jubilant Biosys Limited. The combined entity will operate as Jubilant Biosys Limited. The merger will simplify operations and provide customers with a single brand access for a wide range of discovery, IND and PR&D and GMP development services

    1. Drug Discovery & Development Solutions include the Drug Discovery Services (Jubilant Biosys) business and Proprietary Drug Discovery business (Jubilant Therapeutics)

    D. Business Outlook

    • We have seen substantial improvement in demand in most of our business segments from June 2020 onwards be it Specialty Pharma, CMO, API or Specialty Intermediates
    • Given the strong demand recovery and new business sign-ups, we believe COVID-19 is not likely to have a material impact on our overall performance during FY21, provided the pandemic situation does not materially deteriorate going forward
    • Overall, we expect strong performance in our Pharma, LSI and DDS business in the remaining three quarters of FY21
    • For Pharmaceutical business, we expect substantially better performance in the remaining three quarters of FY21
    • For LSI business, we expect to achieve close to double digit growth in revenues and significant growth in EBIDTA with higher margins and a very healthy cash generation in FY21.